SHP2 (300)

Src homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 proto-oncogene, is a member of the human protein tyrosine phosphatase (PTP) family. Structurally, it comprises three domains: N-terminal and C-terminal SH2 recognition domains and a PTP catalytic domain. SHP2 plays a critical role in modulating various cellular signaling processes that govern metabolism, cell growth, differentiation, migration, transcription, and oncogenic transformation. It interacts with a wide range of cellular molecules and regulates key signaling pathways such as RAS/ERK, PI3K/AKT, JAK/STAT, and PD-1, downstream of multiple receptor tyrosine kinases (RTKs) activated by growth factors and cytokines. Mutations in the PTPN11 gene, leading to alterations in SHP2, have been implicated in numerous human diseases, including Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, and cancers of the breast, lung, and colon. As a result, SHP2 is considered a highly promising target for developing innovative therapies to treat a range of diseases.